#biotech

🏢Release 📈 Stocks

Qidii Shares Rally as Qi601 Clinical Study Validates Microplastic Capture

October 1, 2026 (40 days ago)

Qidii, Inc. reports successful human proof-of-concept for its Qi601 technology, confirming the device's efficacy in capturing microplastics in a peer-reviewed study.

QIDI

🌍 AMERICAS Read More →

📊Earnings 📈 Stocks

CollPlant Biotechnologies Reports Q2 2026 Results and Acquires LightSolver

September 30, 2026 (40 days ago)

CollPlant Biotechnologies expands its reach beyond regenerative medicine, acquiring LightSolver to integrate photonic computing technology alongside its Q2 2026 financial report.

CLGN LIGHTSOLVER

🌍 IL Read More →

🏢Release 📈 Stocks

Eli Lilly Shares Rally as EloraTZP Data Shows 23.3% Weight Loss in Phase 2b

September 30, 2026 (41 days ago)

Eli Lilly's EloraTZP trial results show a 23.3% average weight loss, signaling a potential new benchmark in the company's obesity and type…

LLY

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Q32 Bio Shares Rally on Positive Week 36 SIGNAL-AA Trial Results

September 30, 2026 (41 days ago)

Q32 Bio shares gain momentum as Week 36 trial data confirms the durability of bempikibart, paving the way for optimized, less frequent…

QTTB

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Cresilon Launches TRAUMAGEL Next Generation for Emergency Medical Use

September 30, 2026 (41 days ago)

Cresilon Inc. expands its medical technology portfolio with a compact version of its TRAUMAGEL hemostatic gel, designed to streamline trauma response for…

Cresilon Inc.

🌍 AMERICAS Read More →

🏛️Filing 📈 Stocks

Connect Biopharma Files 8-K Disclosure Regarding Material Corporate Events

September 30, 2026 (41 days ago)

Connect Biopharma Holdings Ltd (CNTB) has filed an 8-K with the SEC, providing updates on Regulation FD disclosures and other material corporate…

CNTB

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

AbbVie Reports Positive Phase 1 Data for Metabolic Drug Candidate ABBV-295

September 30, 2026 (41 days ago)

AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.

ABBV

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Insilico Medicine Targets $36.5B GLP-1 Market With New GIPR Antagonist

September 30, 2026 (41 days ago)

Insilico Medicine advances its drug pipeline with the nomination of ISM1354, aiming to capture market share in the high-growth weight management sector…

Insilico Medicine LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly Retatrutide Phase 3 Trial Shows 20.8% Weight Loss in Diabetics

September 30, 2026 (41 days ago)

Eli Lilly reports positive Phase 3 data for retatrutide, with patients achieving 20.8% weight loss over 80 weeks, strengthening the company's competitive…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Aro Biotherapeutics Appoints Valo Health Executive Brett Blackman to Board

September 29, 2026 (42 days ago)

Aro Biotherapeutics adds Valo Health executive Dr. Brett Blackman to its board, leveraging his extensive background in drug discovery and corporate operations…

Aro Biotherapeutics

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

CSL Seqirus Completes 2026/27 Influenza Vaccine Campaign for U.S. Market

September 29, 2026 (42 days ago)

CSL Seqirus completes its 2026/27 influenza vaccine production cycle, bolstering U.S. supply chains as the company fulfills the bulk of its seasonal…

CSL

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

SeaStar Medical CMO to Present QUELIMMUNE Data at Pediatric Symposium

September 29, 2026 (42 days ago)

SeaStar Medical's CMO highlights QUELIMMUNE therapy for pediatric acute kidney injury in an upcoming oral presentation at a medical symposium.

ICU

🌍 AMERICAS Read More →